ABO血液型不適合移植の新戦略―2012―

出版社： 日本医学館
著者：
発行日： 2012-06-15
分野： 臨床医学：内科  >  血液
ISBN： 9784890447510
電子書籍版： 2012-06-15 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

商品紹介

AOB血液型不適合移植の適応、手術方法、予後･経過、理論的裏づけなどを全国移植施設の有力メンバーが集まり研究会を行い、その内容を各自執筆したもの。肝移植、腎移植を中心とする。

目次

  • ABO血液型不適合移植の新戦略―2012―

    ―目次―

    統計
    　日本におけるABO血液型不適合腎移植の統計2011
    　日本におけるABO血液型不適合肝移植の統計2011

    演題発表
    　1．低抗体価ABO血液型不適合腎移植に対する脾臓摘出／
    　　　抗CD20モノクローナル抗体回避プロトコールの検討
    　2．ABO血液型不適合かつ
    donor specific antibody陽性症例の検討
    　3．国立病院機構千葉東病院における
    　　　ABO血液型不適合生体膵腎同時移植術
    　4．ABO血液型不適合腎移植における免疫順応獲得メカニズム
    　　　―抗体接着により引き起こされるシグナル伝達の観点から
    　5．血液型抗原に対するB細胞免疫応答
    　　　―A型抗原とB型抗原への応答は異なる
    　6．血液型抗原に対する特異的減感作療法の可能性
    　7．成人ABO血液型不適合肝移植後に生じた
    　　　遅発性肝内胆管障害の1例

    ABO血液型不適合移植患者における輸血ガイドライン
    　1．ABO血液型不適合臓器移植患者に対する輸血ガイドライン
    　2．ABO血液型不適合移植患者における輸血ガイドライン
    　　　―肝移植施設へのアンケート調査結果

    総合討論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第18回日本ABO血液型不適合移植研究会 主題 : ABO血液型不適合臓器移植における免疫抑制療法

P.14 掲載の参考文献
1) Takahashi K, Saito K, Tanabe K et al. Multicenter cooperative study group. First report of a seven-year survey on ABO-incompatible kidney transplantation in Japan. Clin Exp Nephrol 5:119-125, 2001.
 
2) Takahashi K, Saito K, Takahara S et al: Excellent longterm outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004.
 
3) Takahashi K, Saito K: The Japanese ABO-incompatible Kidney Transplantation Committee: Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplant 13: 118-122, 2006.
 
4) Takahashi K: ABO-incompatible organ transplantation. Curr Opin Organ Transplant 12:409-414, 2007.
 
5) Takahashi K: Chapter 6. Accommodation in ABO-incompatible kidney transplantation-Why do kidney grafts survive? Accommdation in ABO-incompatible Kidney Transplantation. Elsevier, Amsterdam, 2004, p37-52.
 
6) Takahashi K: A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 19 (supple 14): 76-85, 2005.
 
7) Takahashi K: A new immunosuppressive therapy in ABO-incompatible kidney transplantation besed on a new concept of accommodation. ABO-incompatible Organ Transplantation From JAPAN. (ed Takahahi K), Elsevier, Amsterdam, 2006, p73-87.
 
8) Ogawa H, Mohiuddin MM, Galili U et al: Mouse-heart grafts expressing an incompatible carbohydrate antigen. II Transition from accommodation to tolerance. Transplantation 77: 366-373, 2004.
PubMed
9) Galili U: Xenotransplantation and ABO-incompatible transplantation; the similarities they share. Transfus Apher Sci 35: 45-58, 2006.
PubMed
10) West LJ: B-cell tolerance following ABO-incompatible infant heart transplantation. Transplantation 81:301-307, 2006.
PubMed
11) Takahashi K: Chapter 8. Timing of the start of immunosuppressive therapy (duration of desensitization therapy). Accommodation in ABO-incompatible Kidney Transplantation. Elsevier, Amsterdam, 2004, p94-95.
 
12) Takahashi K:ABO-incompatible kidney transplantation-Establishing a scientific framework. Elsevier, Amsterdam, 2007, p86.
 
13) Saito K, Nakagawa Y, Takahashi K et al: Pinpoint targeted immunosuppression; Anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplant 13: 111-117, 2006.
 
14) Takahashi K: Recent findings of ABO-incompatible kidney transplantation-Classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-bloog group-related antigens during critical period preceding establishment of accommodation. Clin Exp Nephrol 11:128-141, 2007.
 
15) Tyden G, Kumlien G, Genberg H et al: ABO-incompatible kidney transplantation without splenectomy using antigen-specific immunoadsorption and rituximab. Am J Transplant 5:145-148, 2005.
PubMed
16) Kobayashi T, Saito K: A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation 13:136-140, 2006.
 
17) Alexandre GPJ, Squifflet JP, Bruyere MDE et al: Splenectomy as a prerequisite for human ABO-incompatible renal transplantation. Transplant Proc 17:138-143, 1985.
 
18) Irei T, Ohdan H, Zhou W et al.: The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110:4567-4575, 2007.
 
19) Tasaki M, Yoshida Y, Miyamoto M et al.: Identification and characterization of major proteins carrying ABO blood group antigens in the human kidney. Transplantation 87: 1125-1133, 2009.
PubMed
20) Takahashi K, Saito K, Nakagawa Y, Tasaki M, Imai N, Hara N: Mechanism of acute antibody-mediated rejection in ABO-incompatible kidney transplantation: which anti-A/anti-B antibodies are responsible, natural or de novo? Transplantation 89: 635-637, 2010.
PubMed
P.26 掲載の参考文献
1) Ishida H, Furusawa M, Murakami T et al.: Outcome of an ABO-incompatible renal transplant without splenectomy. Transplant Int 15: 56-58, 2002.
PubMed
2) Squifflet JP, De Meyer M, Malaise J et al.: Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Exp Clin Transplant 2: 208-213, 2004.
PubMed
3) Takahashi K, Saito K, Takahara S et al.: Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4: 1089-1096, 2004.
PubMed
4) Sawada T, Fuchinoue S, Teraoka S:Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 74: 1207-1210, 2002.
 
5) Tyden G, Kumlien G, Fehrman I: Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantaion 76: 730-743, 2003.
 
6) Fuchinoue S, Ishii Y, Sawada T et al: The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation 91: 853-857, 2011.
PubMed
7) Shimmura H, Tanabe K, Ishikawa N et al.: Role of anti-A/ B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 70: 1331-1335, 2000.
 
8) 新村浩明, 川口洋, 飯塚淳平・他:脾臓摘出せずリツキシマブも投与しなかったABO血液型不適合生体腎移植の1例. 今日の移植 19:469-472, 2006.
Medical*Online
P.32 掲載の参考文献
1) Okamoto M, Wakabayashi Y, Higuchi A, Kadotani Y, Ogino S et al.: Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. Transplant Proc 35: 859-860, 2005.
 
2) 牛込秀隆, 吉村了勇:腎移植における免疫抑制療法. 腎移植のすべて. (高橋公太・編), Medical view , 2009, p258-263.
 
3) Kaihara S, Okamoto M, Akioka K, Ogino S, Higuchi A et al: Improved graft survival in ABO-incompatible living donor kidney transplantation. Transplant Proc 37: 1804-1805, 2005.
PubMed
4) 岡本雅彦:免疫抑制法と感染症:その対策-ミゾリビン. 今日の移植 20:280-283, 2007.
Medical*Online
5) 岡本雅彦, 鈴木智之, 藤木真人, 昇修治, 牛込秀隆・ 他:リツキシマブを用いたABO血液型不適合腎移植症例の検討. ABO血液型不適合腎移植の新戦略-2009. (高橋公太, 田中紘一・編), 日本医学館, p43-49, 2009.
 
6) Ushigome H, Okamoto M, Koshino K, Nobori S, Okajima Het al.: Findings of graft biopsy specimens within 90 days after ABO blood group incompatible living donor kidney transplantation compared with ABO-identical and non-identical transplantation. Clin Transplant 24 (Suppl 22): 16-21, 2010.
 
P.39 掲載の参考文献
1) Otsuki K, Yoshikawa K, Kenmochi T, Maruyama M, Akutsu N et al.: Evaluation of segmental pancreatic function using 11C-methionine positron emission tomography for safe living donor operation of pancreas transplantation. Transplant Proc 43: 3273-3276, 2011.
PubMed
2) Otsuki K, Yoshikawa K, Kenmochi T, Saigo K, Maruyama Met al, : Evaluation of pancreatic function in normal pancreas as living-related donors and type 1 diabetic pancreas as recipients for pancreas transplantation using 11c-methionine positron emission tomography. Pancreas 39: 418-419, 2010.
 
3) Sampaio MS, Poommipanit N, Cho YW, Shah T, Bunnapradist S: Transplantation with pancreas after living donor kidney vs. living donor kidney alone in type 1 diabetes mellitus recipients. Clin Transplant 24: 812-820, 2010.
PubMed
4) Axelrod DA, McCullough KP, Brewer ED, Becker BN, Segev DL, Rao PS: Kidney and pancreas transplantation in the United States, 1999-2008: the changing face of living donation. Am J Transplant 10 (4 Pt 2): 987-1002, 2010.
 
5) Kenmochi T, Asano T, Maruyama M, Saigo K, Akutsu N et al.: Living donor pancreas transplantation in Japan. J Hepatobiliary Pancreat Sci 17: 101-107, 2010.
PubMed
6) Maruyama M, Kenmochi T, Akutsu N, Saigo K, Iwashita T et al.: Laparoscopic-assisted distal pancreatectomy and nephrectomy from a live donor. J Hepatobiliary Pancreat Sci 17: 193-196, 2010. Epub 2010 Jan 19.
 
7) Suzuki A, Kenmochi T, Maruyama M, Saigo K, Akutsu N et al.: Evaluation of quality of life after simultaneous pancreas and kidney transplantation from living donors using short form 36. Transplant Proc 40: 2565-2567, 2008.
PubMed
8) Kenmochi T, Saigo K, Maruyama M, Akutsu N, Iwashita T et al.: Results of kidney transplantation from ABO-incompatible living donors in a single institution. Transplant Proc 40: 2289-2291, 2008.
 
9) Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC: Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 61: 827-837, 1967.
PubMed
10) Sutherland DE, Goetz FC, Najarian JS: Living-related donor segmental pancreatectomy for transplantation. Transplant Proc 12: 19-25, 1980.
 
11) Gruessner RW, Sutherland DE: Simultaneous kidney and segmental pancreas transplants from living related donors-the first two successful cases. Transplantation 61: 1265-1268, 1996.
PubMed
12) Gruessner RW, Kandaswamy R, Denny R: Laparoscopic simultaneous nephrectomy and distal pancreatectomy from alive donor. J Am Coll Surg 193: 333-337, 2001.
 
13) Tojimbara T, Teraoka S, Babazono T, Sato S, Nakamura M et al.: Long-term outcome after combined pancreas and kidney transplantation from non-heart-beating cadaver donors. Transplant Proc 30: 3793-3794, 1998.
PubMed
14) Sutherland DE, Gruessner R, Gillingham K, Moudry-Munns K, Dunn D et al.: A single institution's experience with solitary pancreas transplantation: a multivariate analysis of factors leading to improved outcome. Clin Transpl: 141-152, 1991.
 
15) Gruessner AC, Barrou B, Jones J, Dunn DL, Moudry-Munns K et al: Donor impact on outcome of bladder-drained pancreas transplants. Transplant Proc 25: 3114-3115, 1993.
PubMed
16) Gruessner RW, Sutherland DE, Drangstveit MB, Bland BJ, Gruessner AC: Pancreas transplants from living donors: short-and long-term outcome. Transplant Proc 33: 819-820, 2001.
 
17) Sutherland DE, Dunn DL, Goetz FC, Kennedy W, Ramsay RC et al.:A 10-year experience with 290 pancreas transplants at a single institution. Ann Surg 210: 274-285, 1989.
 
18) Sutherland DE, Gruessner RW, Dunn DL, Matas AJ, Humar A et al.: Lessons leamed from more than 1, 000 pancreas transplants at a single institution. Ann Surg 233: 463-501, 2001.
 
19) Sollinger HW, Odorico JS, Knechtle SJ, D'Alessandro AM, Kalayoglu M, Pirsch JD: Experience with 500 simultaneous pancreas-kidney transplants. Ann Surg 228: 284-296, 1998.
 
20) Gruessner AC, Sutherland DE: Pancreas transplant out-comes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clin Transpl: 45-56, 2008.
 
P.48 掲載の参考文献
1) Galili U: Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplantation 78(8): 1093-1098, 2004.
PubMed
2) Zhang X, Reed EF: Effect of antibodies on endothelium. Am J Transplant 9(11): 2459-2465, 2009.
PubMed
3) Jindra PT, Jin YP, Rozengurt E, Reed EF: HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 180(4): 2357-2366, 2008.
 
4) Zhang X, Rozengurt E, Reed EF: HLA class I molecules partner with integrin β4 to stimulate endothelial cell proliferation and migration. Sci Signal 3(149): ra85, 2010.
 
5) Iwasaki K, Miwa Y, Haneda M, Uchida K, Nakao A, Kobayashi T: Significance of HLA class I antibody-induced antioxidant gene expression for endothelial cell protection against complement attack. Biochem Biophys Res Commun 391(2): 1210-1215, 2010.
 
6) O'Donnell J, Mille-Baker B, Laffan M: Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. J Vasc Res 37(6): 540-547, 2000.
 
7) Park WD, Grande JP, Ninova D, Nath KA, Platt JL et al.: Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 3: 952-960, 2003.
PubMed
8) Grubbs BC, Benson BA, Dalmasso AP:Characteristics of CD59 upregulation induced in porcine endothelial cells by alphaGal ligation and its association with protection from complement. Xenotransplantation 10: 387-397, 2003.
PubMed
9) Griesemer AD, Okumi M, Shimizu A et al.: Upregulation of CD59: potential mechanism of accommodation in a large animal model. Transplantation 87: 1308-1317, 2009.
 
10) Iwasaki K, Miwa Y, Ogawa H et al.: Comparative study on signal transduction in endothelial cells after anti-A/B and HLA antibody reaction: Implication of accommodation. Transplantation 93(4): 390-397, 2012.
 
11) Kobayashi T, Maruya E et al.: Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation. Hum Immunol 72(1): 11-17, 2011.
PubMed
P.55 掲載の参考文献
1) Irei T, Ohdan H, Zhou W, Ishiyama K, Tanaka Y, Ide K et al.: The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110(13): 4567-4575, 2007.
 
2) 齋藤和英, 高橋公太:日本におけるABO血液型不適合腎移植の統計2009. ABO血液型不適合移植の新戦略-2010. 日本医学館, 2010, p3-16.
 
3) Ohdan H, Swenson KG, Kruger Gray HS, Yang YG, Xu Y, Thall AD et al.: Mac-1-negative B-1b phenotype of natural antibody-producing cells, including those responding to Gal alpha 1, 3Gal epitopes in alpha 1, 3-galactosyl-transferase-deficient mice. J Immunol 165(10): 5518-5529, 2000.
PubMed
4) Zhou W, Ohdan H, Tanaka Y, Hara H, Tokita D et al.: NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol 12(1): 9-18, 2003.
PubMed
5) Treon SP, Shima Y, Raje N et al: Interferon-g induces CD20 expression on multiple myeloma cells via induction of Pu. 1 and augments rituximab binding to myeloma cells. Blood 94(Suppl1): 119a, 2000.
 
6) Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. Embo J 7: 711-717, 1988.
 
P.62 掲載の参考文献
1) Irei T, Ohdan H, Zhou W, Ishiyama K, Tanaka Y et al.: The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110: 4567-4575, 2007.
 
2) 田澤宏文・伊禮俊充・五十嵐友香・田中友加・尾上隆司・他:広島大学におけるABO血液型不適合肝移植の現況とiNKT細胞制御による特異的減感作療法の可能性. ABO血液型不適合移植の新戦略-2011. (高橋公太, 田中紘一・編), 日本医学館, 2011, p48-56.
 
3) Galli G, Nuti S, Tavarini S, Galli-Stampino L, De Lalla C et al.: CD1d-restricted help to B cells by human in variant natural killer T lymphocytes. J Exp Med 197: 1051-1057, 2003.
 
4) Barral P, Eckl-Doma J, Harwood NE, De Santo C, Salio M et al.: B cell receptor-mediated uptake of CD 1 d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc Natl Acad Sci USA 105: 8345-8350, 2008.
 
5) Tahara H, Ide K, Basnet NB, Tanaka Y, Matsuda H et al.: Immunological property of antibodies against N-glycolyl-neuraminic acid epitopes in cytidine monophospho-N-acetylneuraminic acid hydroxylase-deficient mice. J Immunol 184: 3269-3275, 2010.
 
6) Zhou W, Ohdan H, Tanaka Y, Hara H, Tokita D et al.: NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol 12: 9-18, 2003.
PubMed
7) Zhou D, Mattner J, Cantu C 3rd, Schrantz N, Yin N et al.: Lysosomal glycosphingolipid recognition by NKT cells. Science 306: 1786-1789, 2004.
PubMed
8) Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y et al.: CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626-1629, 1997.
PubMed
9) Ohdan H, Swenson KG, Knlger Gray HS, Yang YG, Xu Y et al.: Mac-1-negative B-1b phenotype of natural antibody-producing cells, including thosc responding to Gal alpha 1, 3Gal epitopes in alpha 1, 3-galactosyltransferase-deficient mice. J Immunol 165: 5518-5529, 2000.
 
10) Deguchi T, Tanemura M, Miyoshi E, Nagano H, Machida T et al.: Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer. Cancer Res 70: 5259-5269, 2010.
PubMed
11) Oliva JP, Valdes Z, Casaco A, Pimentel G, Gonzalez J et al.: Clinical evidences of GM3(NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m) Tc. Breast Cancer Res Treat 96: 115-121, 2006.
PubMed
P.68 掲載の参考文献
1) Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M:Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 47: 143-152, 2008.
PubMed
2) Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S et al.: Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73: 1959-1961, 2002.
PubMed
3) 大島剛, 田邉稔, 河地茂行, 尾原秀明, 篠田昌宏・他:慶応義塾大学におけるABO血液型不適合生体肝移植の現況とあらたな工夫. ABO血液型不適合移植の新戦略-2011. (高橋公太, 田中紘一・編), 日本医学館, 2011, p62-67.
 
4) Ryu CH, Lee SK: Biliary strictures after liver transplantation. Gut and Liver 5: 133-142, 2011.
PubMed
P.74 掲載の参考文献
1) 日本赤十字社:「輸血療法の実施に関する指針」ならびに「血液製剤の使用指針」(原版2005年9月. 2007年7月, 2007年11月, 2009年2月改訂)
 
2) 日本麻酔科学会, 日本輸血・細胞治療学会:危機的出血への対応ガイドライン. http://www.anesth.or.jp/guide/pdf/kikitekiGL2.pdf
 

書評

最近チェックした商品履歴

Loading...